Heart Valve Disease Deaths Reverse Decades-Long Decline, Projected to Stay Elevated Through 2040

New preliminary research shows that after nearly two decades of decline, death rates from valvular heart disease among U.S. adults 65 and older have risen since 2018 and are projected to remain elevated through 2040, demanding earlier detection and equitable care.

Houston Metrowire Staff
••Healthcare
Heart Valve Disease Deaths Reverse Decades-Long Decline, Projected to Stay Elevated Through 2040

Death rates from valvular heart disease among U.S. adults ages 65 and older have reversed a nearly two-decade decline, rising from 104 to more than 109 deaths per 100,000 people between 2018 and 2023, according to preliminary research presented at the American Heart Association’s Scientific Sessions 2026 in Chicago. The findings carry weight because they signal that hard-won progress against a condition affecting millions is stalling, even as treatment options have advanced.

Researchers analyzed mortality data from the U.S. Centers for Disease Control and Prevention’s WONDER database for 1999 through 2023, covering 1.2 million heart valve disease-related deaths among adults 65 and older. After peaking at 123.2 deaths per 100,000 in 1999, rates fell to their lowest levels just before the pandemic, then climbed to 109.2 per 100,000 in 2023. Using Joinpoint regression software and forecasting models, the team projected that rates will remain around that elevated level through 2040 rather than resume their earlier decline.

The burden is not evenly distributed. Men had higher death rates than women (124.7 versus 103.1 per 100,000), and non-Hispanic white adults had the highest rates among racial and ethnic groups analyzed (122.4 per 100,000). Adults in nonmetropolitan areas fared worse than those in metropolitan areas (120.5 versus 110.1 per 100,000). Adults 85 and older had more than 15 times the death rate of those 65 to 69 in 1999. Notably, newer generations saw improvements in their late 60s that did not persist into very old age, with higher death rates at 85 and older than earlier generations at the same age.

“The recent reversal of progress in valvular heart disease mortality is especially alarming in light of the substantial advances in treatment achieved over the past decade and a half,” said Sreekanth Vemulapalli, M.D., a volunteer member of the American Heart Association’s Target: Aortic Stenosis Scientific Advisory Group and associate professor of medicine at Duke University. That disconnect, he said, highlights the need for quality improvement and education to boost awareness, care delivery and outcomes.

The American Heart Association has launched initiatives to address the gap. In 2020 it introduced Target: Aortic Stenosis™ to support earlier and more accurate diagnosis and timely treatment, and in 2025 it launched the Heart Valve Initiative, a national effort to identify and treat patients sooner. According to the Association’s 2026 Heart Disease and Stroke Statistics, more than 80 million people worldwide live with heart valve disease, which contributes to more than 57,000 U.S. deaths each year.

Study author Hritvik Jain, M.D., a resident physician at Allegheny General Hospital in Pittsburgh, said the decades-long decline has stopped and that the focus must shift to earlier detection, timely treatment and equitable access to specialized valve care, particularly for the oldest adults and rural communities. The research is considered preliminary until published in a peer-reviewed journal, and the authors note limitations including reliance on death-certificate coding and possible pandemic effects. The abstract and Online Program Planner are available for further detail.

Blockchain Registration

QR Code for Blockchain Registration